Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 24, 2021
Hackensack Meridian Health, New Jersey's largest, most comprehensive and integrated health network, and Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., have entered into a...
-
Apr 19, 2021Lecanemab Phase 3 Clarity AD Clinical Trial Completed Enrollment
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...
-
Apr 16, 2021Twenty-one presentations featuring data and information on investigational lecanemab in early Alzheimer's disease, DAYVIGO® (lemborexant) CIV in insomnia, FYCOMPA® (perampanel) CIII in epilepsy and investigational lorcaserin in Dravet Syndrome
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from the company's deep neurology pipeline and portfolio, including Alzheimer's disease, insomnia and...
-
Mar 16, 2021
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that anti-microtubule binding region (MTBR) tau antibody E2814, which was created from collaboration research...
-
Mar 5, 2021- Oral presentations and posters highlighting Eisai's investigational novel therapies and immunoassay system being studied for Alzheimer's disease and its clinical symptoms
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of data and information from the company's robust Alzheimer's disease (AD) pipeline, including...
Jan 29, 2021The new Prescription Drug User Fee Act (PDUFA) action date set by the FDA is June 7, 2021CAMBRIDGE, Mass. and TOKYO, January 29, 2021 (GLOBE NEWSWIRE) – Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has...
-
Dec 7, 2020Key data results:
Eisai Inc. presented 52-week seizure freedom data related to its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2020 American Epilepsy Society (AES) Annual Meeting virtual conference....
-
Dec 1, 2020EMBARGOED UNTIL: 9:00 AM EST on December 4
Eisai Inc. announced today that new data on its antiepileptic drug FYCOMPA® (perampanel) CIII will be presented at the 74th American Epilepsy Society (AES) Annual Meeting to be held from December...
-
Nov 2, 2020Nine presentations will highlight Eisai's investigational novel therapies being studied to treat Alzheimer's disease and its clinical symptoms
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and research from the company's Alzheimer's disease (AD) pipeline, including...
-
Sep 30, 2020Eisai Continues MOMENTUM 2 Expanded Access Program (Study 405) for Patients Previously Prescribed Lorcaserin to Treat Dravet and Other Refractory Epilepsies
Eisai Inc. announced today that, after consulting with the U.S. Food and Drug Administration (FDA), the Company has initiated a Phase 3 clinical study, MOMENTUM 1 (Study 304, NCT number pending),...
-
Aug 28, 2020New analyses of long-term data explores the efficacy and safety of DAYVIGO over 12 months among adults ages 65 and older and in perimenopausal women as well as fatigue severity
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced findings from several post hoc analyses of DAYVIGO™ from the Phase 3 SUNRISE 1 and 2 clinical studies and...
-
Aug 24, 2020Nine presentations, including a long-term efficacy and safety analysis of DAYVIGO in adults ages 65 and older and interim results from a pilot study on the transition from zolpidem to DAYVIGO, to be shared at the meeting
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced it will present new DAYVIGO™ (lemborexant) CIV research at the SLEEP 2020 virtual conference, the 34th annual...
Aug 7, 2020• Priority Review accelerates FDA review time, with a Prescription Drug User Fee Act (PDUFA) target action on March 7, 2021 • If approved, aducanumab would be the first treatment to meaningfully change the course of Alzheimer’s diseaseCAMBRIDGE, Mass. and TOKYO, August 7, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has...
-
Jul 24, 2020- One oral presentation and eight posters, highlighting Eisai's investigational novel therapies being studied to treat Alzheimer's disease (AD) and its clinical symptoms
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of new data and information from the company's robust AD pipeline, including BAN2401 and...
-
Jul 13, 2020
The Alzheimer's Clinical Trials Consortium (ACTC), Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, United...
-
Jul 8, 2020If approved, aducanumab would be the first treatment with the potential to meaningfully change the course of Alzheimer’s disease
CAMBRIDGE, Mass. and TOKYO, July 8, 2020 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that Biogen has completed the submission of a Biologics...
-
Jun 1, 2020
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the availability of DAYVIGO® (lemborexant) CIV for the treatment of adults with insomnia, characterized by...
-
Feb 13, 2020
Eisai Inc. announced that it will voluntarily withdraw from the market and discontinue sales of BELVIQ® (lorcaserin HCl) CIV and BELVIQ XR (lorcaserin HCl) CIV in the U.S. This action is being...
-
Dec 27, 2019
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that JAMA Network Open (www.jamanetwork.com) published results of SUNRISE 1 (Study 304), a pivotal Phase 3...
-
Dec 23, 2019Approval Based on Robust Clinical Development Program That Included Two Pivotal Trials of Nearly 2,000 Patients
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced the U.S. Food and Drug Administration (FDA) approved DAYVIGO™ (lemborexant) 5 mg and 10 mg for the treatment of...
-
Dec 10, 2019
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced that new data findings for two investigational assets in its robust dementia pipeline were presented at the 12th...
-
Dec 9, 2019Eisai presents key data at the 2019 American Epilepsy Society Annual Meeting
Eisai Inc. presented the latest healthcare economic (HCEI) data for FYCOMPA® (perampanel) CIII at the 2019 American Epilepsy Society Annual Meeting in Baltimore, Maryland. Cumulatively, more than...
-
Dec 9, 2019Key data results:
Eisai Inc. presented new seizure freedom and adherence data related to its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2019 American Epilepsy Society Annual Meeting in Baltimore....
-
Dec 2, 2019New Data from Eisai's Robust Dementia Pipeline Will Be Shared, Including Analyses of Investigational Alzheimer's Disease Compounds and Diagnostic Methods
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today new data from the company's rich dementia pipeline, including BAN2401, lemborexant and diagnostics methods, will...
-
Nov 25, 2019Key presentations include:
Eisai Inc. today will present FYCOMPA® (perampanel) CIII data on convulsive seizure freedom and additional analyses of FYCOMPA at the upcoming American Epilepsy Society Annual Meeting taking...
-
Nov 12, 2019Ella the Jellyfish Brings Comfort and Support to Children with LGS as well as their Families and Caregivers
Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd., today announced the launch of Ella the Jellyfish, the first Amazon Alexa skill designed for those affected by Lennox-Gastaut Syndrome (LGS). The...
- Oct 22, 2019New analysis of larger dataset showed that aducanumab reduced clinical decline in patients with early Alzheimer’s disease as measured by the pre-specified primary and secondary endpoints
Cambridge, Mass. and Tokyo, Japan – October 22, 2019 – Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that, after consulting with the U.S. Food and Drug...
-
Sep 27, 2019Analysis of 12-month data from Phase 3 SUNRISE 2 assessed the long-term effectiveness and safety of lemborexant in adults with insomnia
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced new effectiveness and safety data from the Phase 3 clinical development program for lemborexant, an...
-
Sep 24, 2019Insomnia or Sleeping Difficulties Negatively Impact Household Cohabitants in Unexpected Ways
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from its company-sponsored survey, titled "How America Sleeps and Wakes," was presented at the 2019...
-
Sep 19, 2019Oral Presentation about Results from First Phase 3 Head-to-Head Study with Pre-specified Endpoints vs. Zolpidem ER (SUNRISE 1)
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announced that new long-term, Phase 3 data and additional analyses of lemborexant will be highlighted in eight...
-
Sep 13, 2019Discontinuation of studies based on Data Safety Monitoring Board recommendation
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...
-
Jul 11, 2019
In the news release, New Data in 2 Oral and 13 Poster Presentations about Eisai's Latest Dementia Pipeline, Including BAN2401, Elenbecestat and Lemborexant, to be Presented at Alzheimer's...
-
Jul 9, 2019New Research Center Focused on Immunotherapy for Dementia
Eisai Inc., the U.S. subsidiary of Eisai Co., Ltd., announced today the opening of its Eisai Center for Genetics Guided Dementia Discovery ("G2D2"), a new exploratory research facility located in...
-
Jun 25, 2019- Results of the FREEDOM Study (Study 342) presented at the 33rd International Epilepsy Congress (IEC)
Eisai Inc. today announced results from its FREEDOM Study (Study 342), a Phase III open-label study conducted in Japan and South Korea evaluating the efficacy and safety of FYCOMPA® (perampanel)...
-
Jun 13, 2019-Results from the FREEDOM study, evaluating seizure freedom rates of FYCOMPA in new onset patients, including analyses at the 4 mg/day dose
Eisai Inc. today announced that it will present new data for FYCOMPA® (perampanel) CIII, including FREEDOM study results and the final results of one of the pediatric studies that supported the...
-
Jun 11, 2019New Phase 1 study on investigational treatment explores safety of lemborexant in healthy adult and elderly populations, and those with mild obstructive sleep apnea
Eisai Inc. today announced data on the respiratory safety of investigational lemborexant with multiple and single dosing in healthy adult and elderly individuals, as well as in those with mild...
-
Jun 11, 2019New analyses presented at SLEEP 2019 evaluated impact on key insomnia measures, including disease severity, sleep onset, sleep maintenance, and long-term safety, as well as next-day functioning
Eisai Inc. today announced new long-term safety and pooled analyses from the Phase 3 clinical development program for lemborexant, an investigational agent for sleep-wake regulation, currently...
-
May 28, 2019Data to be presented include:
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") today announced eight poster presentations on lemborexant, an investigational agent being studied for the treatment of insomnia, a sleep-wake disorder,...
-
May 13, 2019
The Alzheimer's Clinical Trials Consortium (ACTC) and Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the investigational oral BACE (beta amyloid cleaving...
-
May 9, 2019-- Eisai presents key data from three retrospective real-world analyses at the 2019 American Academy of Neurology (AAN) Annual Meeting
Eisai Inc. presented the latest clinical results on FYCOMPA® (perampanel) CIII, at the 2019 American Academy of Neurology Annual Meeting in Philadelphia, including analyses highlighting the...
-
Apr 30, 2019
Eisai Inc. and Purdue Pharma L.P. today announced that Eisai will buy out Purdue's rights to the worldwide collaboration for the development and commercialization of lemborexant, an...
-
Apr 24, 2019Presentations include:
Eisai Inc. today announced that one oral presentation and 20 poster presentations from its neurology portfolio will be featured at the American Academy of Neurology's (AAN) Annual Meeting, May...
-
Mar 22, 2019
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that seven poster presentations from its Alzheimer's disease/dementia pipeline will be highlighted at the 14th...
-
Mar 22, 2019
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced that a global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in...
-
Mar 11, 2019
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Imbrium Therapeutics L.P., a clinical-stage biopharmaceutical company and operating subsidiary of Purdue Pharma L.P. (President and CEO: Craig...
-
Feb 25, 2019- Proposed updated label includes data from CAMELLIA-TIMI 61, the first completed and largest cardiovascular outcomes trial for a weight loss agent
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) to potentially update the label for BELVIQ® (lorcaserin HCl)...
-
Feb 19, 2019- Embrace2 is the first wrist-worn wearable in the field of epilepsy to be cleared as a medical device for detecting patterns that may be associated with convulsive seizures in children & adults
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Empatica Inc. announced today that they have entered into an agreement in the U.S. to co-promote the Embrace2 smartband...
-
Feb 4, 2019Six-month data show significant improvements in patient-reported measures of sleep onset and sleep maintenance for investigational agent lemborexant
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD, "Purdue Pharma") today announced six-month results from SUNRISE 2, a long-term Phase 3...
-
Jan 22, 2019Lemborexant taken at bedtime had no significant effect on automobile driving performance the next morning in healthy adult and elderly volunteers
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD, "Purdue Pharma") today announced the publication of a Phase 1 safety study evaluating the...
-
Jan 15, 2019
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD, "Purdue Pharma") today announced that a new drug application has been submitted to the U.S....
-
Dec 7, 2018
Eisai announced today that the first investigational drug candidate from their drug discovery collaboration with University College London (UCL) is to enter Phase I clinical trials for Alzheimer's...
-
Dec 4, 2018-- In a real-world, observational, retrospective study of FYCOMPA as a first add-on therapy, 61% (19/31) of patients with generalized seizures achieved seizure freedom, with an overall retention rate of 85% (127/149) at 12 months
Eisai Inc. presented new data on FYCOMPA® (perampanel) CIII at the American Epilepsy Society Annual Meeting in New Orleans which included analyses of convulsive seizure freedom rates in adult and...
Nov 21, 2018Eisai Inc. today announced that it will present FYCOMPA® (perampanel) CIII long-term seizure freedom and pediatric data at the upcoming American Epilepsy Society Annual Meeting taking place from...
- Oct 25, 2018
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, “Biogen”)...
-
Oct 24, 2018
Eisai Inc. the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that they have signed a value-based contract for FYCOMPA® (perampanel) CIII with Oklahoma Health Care Authority...
-
Oct 17, 2018Additional Data from BAN2401 Phase 2 Results to be Presented
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that five oral and two poster presentations from its Alzheimer's disease pipeline, including additional data on...
-
Oct 17, 2018Long-term efficacy and safety evaluation in patients with insomnia, a sleep-wake disorder, met primary and key secondary efficacy objectives
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD "Purdue Pharma") today announced positive topline results from SUNRISE 2, a long-term Phase...
-
Oct 16, 2018Five scientific presentations and a video profiling new Eisai Center in Cambridge, Massachusetts to be presented at conference
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that 5 poster presentations reporting new research on human genetics guided drug discovery will be highlighted at...
Oct 4, 2018- In secondary metabolic analyses of CAMELLIA-TIMI 61, patients with pre-diabetes who were treated with BELVIQ were less likely to develop diabetes and had a greater tendency to achieve normal blood glucose levels compared to patients treated with placeboEisai Inc. announced today new data on prevention and remission of diabetes from the CAMELLIA-TIMI 61 cardiovascular (CV) outcomes trial in patients treated with anti-obesity agent BELVIQ®...
-
Sep 28, 2018- FYCOMPA is an important new option for pediatric patients to potentially improve seizure control
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) expanded the indication of its antiepileptic drug FYCOMPA® (perampanel) CIII for monotherapy and adjunctive use in...
-
Aug 27, 2018- CAMELLIA-TIMI 61 is first large-scale outcomes trial to achieve long-term cardiovascular (CV) safety for a weight loss agent
Eisai Inc. announced today that results from the CAMELLIA-TIMI 61 cardiovascular (CV) outcomes trial in patients treated with BELVIQ® (lorcaserin HCl) CIV 10 mg twice-daily were presented at the...
-
Jul 25, 2018
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...
-
Jul 25, 2018
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...
-
Jul 18, 2018Thirteen presentations to be given including late breaking Phase 2 study results of BAN2401 and elenbecestat
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today that 13 posters and presentations from its robust Alzheimer's disease pipeline, including the Phase 2 clinical...
-
Jul 17, 2018- BELVIQ did not increase incidence of cardiovascular events in study of 12,000 obese and overweight patients
Eisai Inc. announced positive topline results from the CAMELLIA-TIMI 61 cardiovascular outcome trial. This 12,000 patient study of BELVIQ® (lorcaserin HCl) CIV 10 mg twice-daily was conducted at...
- Jul 9, 2018
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announces today the results of the BAN2401 Phase II clinical study, Study 201(ClinicalTrials.gov identifier NCT01767311), will be...
-
Jul 5, 2018- The final analysis at 18 months of the 856 patient Phase II clinical study in early Alzheimer's disease demonstrated statistically significant slowing in clinical decline and reduction of amyloid beta accumulated in the brain
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...
-
Jul 2, 2018Presentation includes data from first-ever Phase 3 head-to-head superiority comparison vs zolpidem ER in patients with a sleep-wake disorder
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD "Purdue Pharma") today announced that they will present data on their investigational...
-
Jun 5, 2018Studies measured postural stability after middle-of-the-night awakening and next morning compared to zolpidem ER, as well as next-morning driving performance
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today presented the results of two key Phase 1 clinical studies of their...
-
Jun 5, 2018RESULTS OF THE PHASE II STUDY DEMONSTRATED A STATISTICALLY SIGNIFICANT DIFFERENCE IN AMYLOID BETA IN BRAIN
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (NASDAQ: BIIB) (Headquarters: Cambridge, Massachusetts, United States, CEO: Michel Vounatsos, "Biogen") announced...
-
May 30, 2018- Designation underscores the need to expand potential treatment options to help certain young patients achieve goal of seizure freedom
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) for Priority Review for its antiepileptic drug FYCOMPA®...
-
May 22, 2018
Companies will present data on: Postural stability after middle-of-the-night awakening and next-morning compared to zolpidem ER Auditory awakening threshold Return to sleep latency compared to...
-
Apr 19, 2018Abstracts presented add to growing body of FYCOMPA data supporting convulsive seizure freedom, and real-world, long-term safety & efficacy data
Eisai Inc. will present six posters on FYCOMPA® (perampanel) CIII at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles from April 21-27. The poster presentations will include...
-
Mar 30, 2018- First step to making FYCOMPA available for children, underscoring Eisai's commitment to epilepsy care for patients of all ages
Eisai Inc. announced today that it has submitted a supplemental New Drug Application (sNDA) for priority review to the U.S. Food and Drug Administration (FDA) for its antiepileptic drug FYCOMPA®...
-
Mar 7, 2018
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today announced positive topline results from multiple studies of lemborexant,...
-
Jan 30, 2018
Eisai Inc. and Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer's disease-associated genetic variants on the behavior of brain cells,...
-
Dec 6, 2017seizures and healthcare utilization associated with perampanel therapy
Eisai Inc. presented eight posters on perampanel (marketed as FYCOMPA® CIII) at the American Epilepsy Society (AES) Annual Meeting in Washington, D.C. The poster presentations included analyses...
Dec 5, 2017Tools now available to help adolescents with epilepsy transition to the adult health care system underscoring Eisai's leadership and commitment to the epilepsy communityThe Child Neurology Foundation (CNF) and Eisai today announced the availability of original resources aimed at helping those living with epilepsy navigate and simplify the transition from their...
-
Nov 22, 2017Data of note includes post-hoc analysis identifying potential predictors of major response to treatment with perampanel
Eisai Inc. announced today the presentation of eight posters on data, including real-world use of perampanel (marketed as FYCOMPA® CIII). These data will be presented at the American Epilepsy...
-
Oct 30, 2017
Eisai Inc. announced today the presentation of three posters during the 10th annual Clinical Trials on Alzheimer's Disease (CTAD) meeting, highlighting data on innovative ways to screen for...
-
Jul 26, 2017- First antiepileptic drug (AED) to apply FDA's regulatory pathway of extrapolation for monotherapy use; FDA proposed using this pathway to get monotherapy options to patients sooner
Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the company's supplemental New Drug Application (sNDA) for FYCOMPA® (perampanel) CIII as monotherapy use...
-
Jul 17, 2017
Eisai Inc. announced today the presentation of eight posters, including safety data on three different compounds in its Alzheimer's disease portfolio, at the Alzheimer's Association International...
-
Jun 21, 2017Lorcaserin Phase IIIb/IV Outcomes Study Assesses Incidence of Major Adverse Cardiovascular Events (MACE) in Patients with Overweight or Obesity
Eisai Inc. today announced that the ongoing investigational CAMELLIA-TIMI 61 study of lorcaserin (marketed as BELVIQ® CIV) will continue as planned, based on the recommendation of an independent...
-
Apr 27, 2017Data to be Presented at the American Academy of Neurology "Best Of" Epilepsy Session
Eisai Inc. announced today the presentation of results from a new meta-analysis of published clinical trials showing that the effect of adjunctive antiepileptic drug (AED) treatment versus placebo...
-
Apr 13, 2017Eisai Announces Perampanel Data in Epilepsy at the 2017 American Academy of Neurology Annual MeetingMeta-analysis on the extrapolation of adult antiepileptic drug efficacy data, including perampanel, to pediatric patients to be featured in "Best Of" oral presentation panel
Eisai Inc. announced today that eight poster presentations featuring data on the safety and efficacy of perampanel (marketed as FYCOMPA® CIII) in a range of seizure types will be presented at the...
Mar 23, 2017Eisai Inc. is pleased to announce that it will be launching the latest "Medikidz Explain Epilepsy," book as part of their participation at the Epilepsy Foundation's National Walk for Epilepsy on...
Jan 4, 2017Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd. (collectively, "Eisai"), announced today that it has reached an agreement with Arena Pharmaceuticals, Inc. to revise the November...
- Dec 19, 2016
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced that Eisai Laboratórios Ltda., a subsidiary of Eisai Inc., has received regulatory approval from the Brazilian Health...
Dec 12, 2016Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of two posters highlighting the latest data on elenbecestat (development code: E2609), its...
- Dec 5, 2016Presentations Include Analysis of Real-World Use and Post-Hoc Analysis of Long-Term Safety and Efficacy
Eisai Inc. announced today new analyses and data on perampanel presented at the 2016 Annual Meeting of the American Epilepsy Society (AES). Perampanel, marketed as FYCOMPA® CIII, is indicated as...
- Dec 5, 2016
Eisai Inc. announced today final results of its Phase 3 open-label two-year study of rufinamide, which were presented at the 2016 Annual Meeting of the American Epilepsy Society (AES) held from...
- Nov 28, 2016
Eisai Inc. announced today the presentation of 12 posters during the 70th annual American Epilepsy Society (AES) Annual Meeting, highlighting data from the company's anti-epileptic drugs FYCOMPA®...
-
Nov 17, 2016
Eisai Inc. announced today that it has received U.S. Food and Drug Administration (FDA) Fast Track designation for the development of E2609, a Beta-secretase Cleaving Enzyme (BACE) inhibitor...
- Nov 3, 2016
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today the presentation of one oral presentation and one poster at Obesity Week(SM) regarding new data on BELVIQ® (lorcaserin...
-
Oct 31, 2016
Eisai Inc. and Purdue Pharma L.P. announced today the initiation of a multi-center, randomized Phase 2 clinical study (Study 202) to evaluate Eisai's internally-discovered oral dual orexin...
- Oct 31, 2016
Eisai Inc. announced today that enrollment has begun in the U.S. for MISSIONAD, a Phase 3 clinical program for E2609, a Beta-secretase Cleaving Enzyme (BACE) inhibitor for patients with early...
- Oct 28, 2016Trials to assess perampanel in those with Lennox-Gastaut Syndrome, a rare form of epilepsy, and in children with partial-onset seizures now enrolling patients
Eisai Inc. announced today the initiation of two multi-center, global Phase 3 clinical trials assessing FYCOMPA® (perampanel) CIII in two different patient populations: patients age 2 years and...
- Oct 26, 2016"Medikidz Explain LGS," endorsed by leading advocacy groups, educates public on rare and severe form of epilepsy
Eisai Inc. today announced the launch of "Medikidz Explain Lennox-Gastaut Syndrome (LGS)," an educational comic book designed to inform people about LGS, a rare type of epilepsy that is usually...
- Oct 3, 2016New FDA-Approved Formulation Offers Patients a Once-Daily Dosing Option for Chronic Weight Management
Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced the availability of BELVIQ XR® (lorcaserin HCl) CIV extended-release 20 mg tablets, a new once-daily dosing option that...
- Sep 26, 2016Application Based on New FDA Communication Supporting Use as Monotherapy for the Treatment of Partial Onset Seizures Based on Extrapolation
Eisai Inc. announced today that it has submitted a supplemental application to the U.S. Food and Drug Administration (FDA) for a proposed label change for its antiepileptic drug FYCOMPA®...
